Australian biopharma Immutep Ltd. saw its stock price jump 165% Dec. 10, as the company reported that adding its eftilagimod alpha (IMP-321, “efti”) to paclitaxel resulted in what the company called a “promising and improving” trend toward increased overall survival in women with metastatic hormone receptor-driven breast cancer.

Suzhou, China-based Kintor Pharmaceutical Ltd. said it's "actively initiating" multiregional phase II/III trials to test a combination of its angiogenesis inhibitor, GT-90001 (ascrinvacumab), and Opdivo (nivolumab) for advanced hepatocellular carcinoma (HCC) after preliminary data showed 40% of patients given the combo so far had partial remissions.

BEIJING – San Diego and Hangzhou, China-based biotech Denovo Biopharma LLC closed a series D financing round to raise nearly ¥300 million (US$46 million) on Dec. 8, just six months after its $83.5 million series C round. Denovo CFO Carrie Chen told BioWorld that the proceeds will be used to “upgrade the technology platform, advance the clinical programs, expand the team and license in new assets.”

Rayzebio Inc. has swiftly followed up its recent $45 million series A round with a $105 million series B round that attracted several top-tier crossover investors.

New and updated preclinical and clinical data presented by biopharma firms at the San Antonio Breast Cancer Symposium, Dec. 8-11, including: Amunix, Astrazeneca, Athenex, Beyondspring, Bold, Briacell, Daiichi Sankyo, Eli Lilly, Evelo, Greenwich, Immutep, Infinity, Medsir, Novartis, Oncolytics, Pharmabcine.